The strains used in this study are the probiotic E. coli Nissle 1917 (ECN) and the archetypal K12 E. coli strain MG1655. Both strains were engineered to exhibit a mutation in the rpsL gene, which is known to confer resistance to streptomycin . Before oral administrations, ECN and MG1655 strains were grown for 6 h in LB broth supplemented with However, there are scarce data exploiting the effects of gut microbiota-derived 5-HT in constipation-related disease. We genetically engineered the probiotic Escherichia coli Nissle 1917 (EcN-5-HT) for synthesizing 5-HT in situ. The ability of EcN-5-HT to secrete 5-HT in vitro and in vivo was confirmed. Thus, the use of strictly defined probiotics, prebiotics and synbiotics may become an alternative form of IBD therapy. There is evidence that treatment with certain probiotic strains, e.g., VSL#3 and Escherischia coli Nissle 1917, is an effective form of therapy to induce remission in patients with mild to moderate UC. So far, the effectiveness Escherichia coli strain Nissle 1917 (EcN) is the most promising one. Human intestinal microflora harbors a dynamic bacterial community with protective functions for the host ( Zhai et al., 2017 ). The intestine acts as the invasion front against foreign substance accumulation via microbial community changes, called “gut remediation” ( Abdel Escherichia coli strain Nissle 1917 (EcN) is a remarkable probiotic bacterium, first described by Alfred Nissle in 1916/17. As the active component of Mutaflor, EcN has been well researched over decades but detailed mechanisms by which EcN confers its probiotic effects are still elusive. Escherichia coli Nissle 1917 (EcN, Mutaflor) is a Gram-negative bacterium widely used as a probiotic strain. Its probiotic potential includes prevention of pathogenic invasion, positive effect on epithelial cells, host smooth muscle cell activity, and host immune response ( Reissbrodt et al., 2009 , Bär et al., 2009 , Kamada et al., 2008 ). The probiotic Escherichia coli strain Nissle 1917 (DSM 6601, Mutaflor), generally considered beneficial and safe, has been used for a century to treat various intestinal diseases. However, Nissle 1917 hosts in its genome the pks pathogenicity island that codes for the biosynthesis of the genotoxin colibactin. Methods and results: We treated stationary-phase E. coli MG1655 with a DNA-damaging fluoroquinolone and co-cultured the cells with probiotic E. coli Nissle following antibiotic removal. We found that E. coli Nissle reduced the survival of fluoroquinolone persisters and their progeny by over three orders of magnitude within 24 h. Mechanism of action in E. coli Nissle1917. In 1917, during World War I, Alfred Nissle from Freiburg, Germany isolated EcN 1917 (O6:K5:H1) from the intestinal microflora of a young soldier who did not develop infectious diarrhea during a severe outbreak of shigellosis Mutaflor® as a probiotic medication was formulated by Prof. Nissle. Mutaflor Probiotics - 100 Capsules. $118.50. Add to Cart. Mutaflor® is a probiotic (capsule) which contains a viable non-pathogenic strain of Escherichia coli (E coli), named Escherichia coli Nissle 1917. It was first isolated in 1917 by Professor Alfred Nissle from the faeces of a soldier during the First World War. It had been noticed that a s15y5A.